NewsOK Local Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Vertex Pharmaceuticals (NQ: VRTX)
181.16 USD  +3.51 (+1.98%)
Streaming Delayed Price  /  Updated: 10:15 AM EDT, Oct 16, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 142,644
Open 178.87
Bid (Size) 181.07 (1)
Ask (Size) 181.25 (1)
Prev. Close 177.65
Today's Range 178.45 - 181.97
52wk Range 136.50 - 194.92
Shares Outstanding 254,830,232
Dividend Yield N/A
Performance
YTD
+18.47%
+18.47%
1 Month
+3.05%
+3.05%
3 Month
-0.03%
-0.03%
6 Month
+14.15%
+14.15%
1 Year
+17.10%
+17.10%
Top News
More News
These 2 Biotechs Poised To Top Quarterly Views Amid Slowdown
Gilead Sciences and Amgen are poised to top third-quarter views, but biotech companies will broadly face sequential declines on currency headwinds, an analyst predicted Monday. Read More
from Investor's Business Daily
Merck Has A Keytruda Dependence Problem: Could A Megamerger Fix It?
Does Jones component Merck could seek a megamerger with Amgen or AstraZeneca to diversify from blockbuster cancer treatment Keytruda, an analyst suggested Thursday. Read More
from Investor's Business Daily
More News
Read More
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
from GlobeNewswire News Releases
Crispr Stock Flies 13% After FDA Clears It To Begin Gene-Editing Test
from Investor's Business Daily
Why These 3 Biotech Companies Are Likely To Top Third-Quarter Estimates
from Investor's Business Daily
These Biotechs Are Poised As 'Standouts' Heading Into Earnings
from Investor's Business Daily
Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines
from Business Wire News Releases
After-hours buzz: SQ, FLR & more
category Business/Earnings , Fluor Corp , Earnings , and 11 more.
from CNBC.com News
Why CRISPR Therapeutics Stock Is Heading Higher Today
category Market News , CRSP , VRTX
from Motley Fool
Better Buy: Crispr Therapeutics AG vs. Editas
category Market News , EDIT , AGN , and 5 more.
from Motley Fool
3 Biotech Stocks With Major Incoming Catalysts
category VRTX , GLPG , BMY , and 4 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.